Non-small-cell lung cancer management and outcomes in France
Author Information
Author(s): Foeglé J, Hédelin G, Lebitasy M P, Purohit A, Velten M, Quoix E
Primary Institution: Université Louis Pasteur, Strasbourg, France
Hypothesis
Does the addition of chemotherapy improve survival in patients with non-small-cell lung cancer over time?
Conclusion
The addition of chemotherapy did not lead to an overall improvement in survival for non-small-cell lung cancer patients in the studied population.
Supporting Evidence
- The proportion of women and metastatic cases changed significantly over time.
- 5-year survival probability was 15.7% for all patients and 32.6% for those with resectable disease.
- Overall survival did not improve over time despite changes in treatment.
Takeaway
This study looked at lung cancer patients in France and found that even though treatments changed, patients didn't live longer overall.
Methodology
A retrospective population-based study analyzing medical records of 1738 patients diagnosed with NSCLC from 1982 to 1997.
Potential Biases
Potential selection bias due to exclusion of patients with missing medical records.
Limitations
The study did not account for performance status due to missing data, which may have influenced survival outcomes.
Participant Demographics
The median age of participants was 63 years, with a sex ratio of approximately 10.6 males to 1 female at the beginning of the study period.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website